Literature DB >> 33466843

Endocrine Toxicities of Antineoplastic Therapy.

Giulia Puliani1,2, Marialuisa Appetecchia1.   

Abstract

In recent years, the prognosis of many solid tumors has improved markedly thanks to new treatment strategies, including tyrosine kinase inhibitors (TKIs) and immunotherapy [...].

Entities:  

Year:  2021        PMID： 33466843      PMCID： PMC7830439          DOI： 10.3390/cancers13020294

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN： 2072-6694            Impact factor:   6.639


  30 in total

Review 1.  Tyrosine kinases as targets for cancer therapy.

Authors:  Daniela S Krause; Richard A Van Etten
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

Review 2.  Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions.

Authors:  Frédéric Castinetti; Frédéric Albarel; Françoise Archambeaud; Jérome Bertherat; Benjamin Bouillet; Perrine Buffier; Claire Briet; Bertrand Cariou; Philippe Caron; Olivier Chabre; Philippe Chanson; Christine Cortet; Christine Do Cao; Delphine Drui; Magali Haissaguerre; Ségolène Hescot; Frédéric Illouz; Emmanuelle Kuhn; Najiba Lahlou; Emilie Merlen; Véronique Raverot; Sarra Smati; Bruno Verges; Françoise Borson-Chazot
Journal:  Ann Endocrinol (Paris)       Date:  2018-07-11       Impact factor: 2.478

3.  Altered bone and mineral metabolism in patients receiving imatinib mesylate.

Authors:  Ellin Berman; Maria Nicolaides; Robert G Maki; Martin Fleisher; Suzanne Chanel; Kelly Scheu; Bri-Anne Wilson; Glenn Heller; Nicholas P Sauter
Journal:  N Engl J Med       Date:  2006-05-11       Impact factor: 91.245

Review 4.  Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolism.

Authors:  Bruno Vergès; Thomas Walter; Bertrand Cariou
Journal:  Eur J Endocrinol       Date:  2014-02-01       Impact factor: 6.664

5.  The skeletal effects of the tyrosine kinase inhibitor nilotinib.

Authors:  Susannah O'Sullivan; Jian-Ming Lin; Maureen Watson; Karen Callon; Pak Cheung Tong; Dorit Naot; Anne Horne; Opetaia Aati; Fran Porteous; Greg Gamble; Jillian Cornish; Peter Browett; Andrew Grey
Journal:  Bone       Date:  2011-04-29       Impact factor: 4.398

Review 6.  Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors.

Authors:  Perrine Buffier; Benjamin Bouillet; Sarra Smati; Francoise Archambeaud; Bertrand Cariou; Bruno Verges
Journal:  Ann Endocrinol (Paris)       Date:  2018-08-01       Impact factor: 2.478

Review 7.  THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors.

Authors:  Poupak Fallahi; Silvia Martina Ferrari; Giusy Elia; Francesca Ragusa; Sabrina Rosaria Paparo; Stefania Camastra; Valeria Mazzi; Mario Miccoli; Salvatore Benvenga; Alessandro Antonelli
Journal:  Eur J Endocrinol       Date:  2021-01       Impact factor: 6.664

Review 8.  Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.

Authors:  Jun Gong; Alexander Chehrazi-Raffle; Srikanth Reddi; Ravi Salgia
Journal:  J Immunother Cancer       Date:  2018-01-23       Impact factor: 13.751

9.  Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.

Authors:  Romualdo Barroso-Sousa; William T Barry; Ana C Garrido-Castro; F Stephen Hodi; Le Min; Ian E Krop; Sara M Tolaney
Journal:  JAMA Oncol       Date:  2018-02-01       Impact factor: 31.777

Review 10.  Interventions for sexual dysfunction following treatments for cancer in women.

Authors:  Bridget Candy; Louise Jones; Victoria Vickerstaff; Adrian Tookman; Michael King
Journal:  Cochrane Database Syst Rev       Date:  2016-02-02
View more
  1 in total

1.  Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System.

Authors:  Emanuel Raschi; Michele Fusaroli; Valentina Giunchi; Andrea Repaci; Carla Pelusi; Veronica Mollica; Francesco Massari; Andrea Ardizzoni; Elisabetta Poluzzi; Uberto Pagotto; Guido Di Dalmazi
Journal:  Cancers (Basel)       Date:  2022-09-22       Impact factor: 6.575
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.